glp 1 drugs non prescription Comparing Ozempic, Wegovy and Other GLP-1 GLP-1 Agonists: A Comprehensive Overview

Versace A, Andreazza AC, Young LT, Fournier JC, Almeida JR, Stiffler RS, et al

2 The addition of semaglutide to the Food and Drug Administration (FDA) shortage list from 2022 to February 2025, and tirzepatide to the same list from 2022 to December 2024, gave compounding pharmacies permission by the FDA to produce exact duplicates to ensure continuity of treatment until production met demand

When a drug is in shortage, compounders may be able to legally create a compounded version of a drug as long as they meet certain requirements

Practice Pearl(s) The dosing regimen of glucagon-like peptide-1 (GLP-1) agonists is characterized by careful initiation and titration to ensure optimal glycemic control while minimizing potential adverse effects

Glucagon concentrations in plasma decreased under treatment with SAR425899 although the variability was high